



REKAP DAFTAR HADIR KULIAH PAKAR BLOK 7/SISTEM RESPIRASI & PENGENALAN KETERAMPILAN MEDIK  
SEMESTER GASAL TAHUN AKADEMIK 2020/2021  
PERIODE : 21 SEPTEMBER - 20 OKTOBER 2020

NO	NAMA DOSEN	DEPARTEMEN	JLH JAM RENCANA	BLOK 7 & PKM											REALISASI KP
				SEPTEMBER			OKTOBER								
1	dr. June L. Nainggolan, MS, SpKL	Biomedik Dasar	4	21	24	28	1	5	8	12	15	19	4		
2	dr. Frisca Angreni, M.Biomed.	Anatomi	4	4	-	-	-	-	-	-	-	-	4		
3	dr. Wawat Hartaswati, MS, PHK	Anatomi	4	4	-	-	-	-	-	-	-	-	4		
4	dr. Nur Nunu Prihantini, M.Si	Biokimia Kedokteran	4	-	4	-	-	-	-	-	-	-	4		
5	dr. Fajar L. Gultom, SpPA	Pato. Anatomi	4	-	4	-	-	-	-	-	-	-	4		
6	dr. Kurnilyanto, SpPD	Ilmu Peny. Dalam	20	-	4	-	-	4	4	4	-	4	20		
7	dr. Ida Bagus Eka Wija Utama, SpA	Ilmu Kes. Anak	4	-	-	-	4	-	-	-	-	-	4		
8	dr. Gregorius Sepatayuda, SpRad	Radiologi	8	-	-	-	4	-	-	4	-	-	8		
9	Prof. Dr. dr. Retno Wahyuningsih, MS, SpParK	Parasitologi	8	-	-	-	4	4	-	-	-	-	8		
10	dr. Trimurti Parnomo, MS, SpMK	Mikrobiologi	4	-	-	-	-	4	-	-	-	-	4		
11	Dra. Lusnia Sri Sunarti, MS	Mikrobiologi	4	-	-	-	-	4	-	-	-	-	4		
12	dr. Erica Gilda Simanjuntak, SpAn	Anestesi	4	-	-	-	-	4	-	-	-	-	4		
13	dr. Belinda J. L. Latumunte, Sp.KFR	Bedah	4	-	-	-	-	-	4	-	-	-	4		
14	dr. Danny E. J. Luhulima, SpPK	Pato. Klinik	4	-	-	-	-	-	4	-	-	-	4		
15	dr. Keswari Aji Patrawati, M.Sc., SpA	Ilmu Kes. Anak	4	-	-	-	-	-	-	4	-	-	4		
16	Dr. Med. dr. Abraham Simatupang, M.Kes.	Farmakologi Terapi	4	-	-	-	-	-	-	-	4	-	4		
17	dr. E. S. Diapari Pohan, SpB - M.Kes.	Bedah	4	-	-	-	-	-	-	-	4	-	4		
18	dr. Jumaini Andriana Sihombing, M.Pd.Ked.	Anatomi	4	-	-	-	-	-	-	-	4	-	4		
19	dr. Erida Manalu, SpPK	Pato. Klinik	4	-	-	-	-	-	-	-	-	4	4		
20	Evy Suryani Arodes, M.Biomed., M.Pd.	Mikrobiologi	4	-	-	-	-	-	-	-	-	4	4		
TOTAL			104												104
PERSENTASI KEHADIRAN KULIAH PAKAR BLOK 7 & KM			100%												



Jakarta, 21 Oktober 2020

Koordinator Blok 7,

dr. Danny E. J. Luhulima, SpPK



# Universitas Kristen Indonesia

## Fakultas Kedokteran

SURAT KEPUTUSAN  
No. : 032/UKI.F5.D/HKP.3.5.6/2020  
tentang

### PENUGASAN TENAGA AKADEMIK DALAM MEMBERIKAN KULIAH PAKAR PIMPINAN FAKULTAS KEDOKTERAN UNIVERSITAS KRISTEN INDONESIA

- MENIMBANG** : Bahwa untuk kelancaran proses belajar mengajar dan meningkatkan mutu pendidikan di FKUKI diperlukan penugasan tenaga akademik FKUKI untuk memberikan Kuliah Pakar
- MENINGAT** : 1. Peraturan Pemerintah No. 60 tahun 1999 tentang Pendidikan Tinggi  
2. Surat Keputusan Dekan FKUKI No. 53/SK/FKUKI/11.2006 tanggal 21 November 2006 tentang Pemberlakuan Kurikulum Berbasis Kompetensi (KBK) di FKUKI  
3. Surat Keputusan Rektor UKI No. 90/UKI.R/SK/SDM.8/2018 tentang pengangkatan Dekan Fakultas Kedokteran UKI  
4. Surat keputusan pengangkatan sebagai tenaga akademik

### MEMUTUSKAN

- MENETAPKAN** : 1. Penugasan dalam memberikan Kuliah Pakar :
- |              |  |
|--------------|--|
| Nama         | dr. Fajar Lamhot Gultom, Sp.PA                       |
| Departemen   | Patologi Anatomi                                     |
| Blok         | 7 (Sistem Pernapasan)                                |
| Judul Materi | Gambaran Patologi Anatomi Kelainan Sistem Pernapasan |
| Semester     | gasal 2020/2021                                      |
| Kelas        | A : 0,21 SKS<br>B : 0,21 SKS                         |
| SKS          | 0,42 SKS   |
2. Apabila dikemudian hari ternyata terdapat kekeliruan dalam Surat Keputusan ini akan diperbaiki sebagaimana mestinya

Asli Surat Keputusan ini disampaikan kepada yang bersangkutan untuk diketahui





Ditetapkan di : Jakarta  
Pada tanggal : 10 September 2020

Dekan,  
  



**Dr. dr. Robert Hotman Sirait, Sp.An.**  
NIP. 1951031 545

Tembusan:

1. Rektor UKI
2. Wakil Dekan Bidang Akademik FKUKI



# Respiratory Tract Pathology



**Fajar L. Gultom**  
**Departemen Patologi Anatomik**  
**FK UKI**  
**September 2020**

## 4

## SISTEM RESPIRASI

## Paru

18	Asma bronkial	4A
35	Atelektasis	2
36	Penyakit Paru Obstruksi Kronik (PPOK) eksaserbasi akut	3B
37	Edema paru	3B
38	Infark paru	1
39	Abses paru	3A
40	Emboli paru	1
41	Kistik fibrosis	1
42	<i>Haematothorax</i>	3B
43	Tumor mediastinum	2
44	Pnemokoni asis	2
45	Penyakit paru intersisial	1
46	<i>Obstructive Sleep Apnea (OSA)</i>	1
32	Efusi pleura	2
33	Efusi pleura masif	3B
34	Emfisema paru	3A
16	Aspirasi	3B
17	Benda asing	2

**COVID-19??**

# SKDI 2012

## **Tingkat Kemampuan 1: mengenali dan menjelaskan**

Lulusan dokter mampu mengenali dan menjelaskan gambaran klinik penyakit, dan mengetahui cara yang paling tepat untuk mendapatkan informasi lebih lanjut mengenai penyakit tersebut, selanjutnya menentukan rujukan yang paling tepat bagi pasien. Lulusan dokter juga mampu menindaklanjuti sesudah kembali dari rujukan.

## **Tingkat Kemampuan 2: mendiagnosis dan merujuk**

Lulusan dokter mampu membuat diagnosis klinik terhadap penyakit tersebut dan menentukan rujukan yang paling tepat bagi penanganan pasien selanjutnya. Lulusan dokter juga mampu menindaklanjuti sesudah kembali dari rujukan.

# SKDI 2012

**Tingkat Kemampuan 3: mendiagnosis, melakukan penatalaksanaan awal, dan merujuk**

## **3A. Bukan gawat darurat**

Lulusan dokter mampu membuat diagnosis klinik dan memberikan terapi pendahuluan pada keadaan yang bukan gawat darurat. Lulusan dokter mampu menentukan rujukan yang paling tepat bagi penanganan pasien selanjutnya. Lulusan dokter juga mampu menindaklanjuti sesudah kembali dari rujukan.

## **3B. Gawat darurat**

Lulusan dokter mampu membuat diagnosis klinik dan memberikan terapi pendahuluan pada keadaan gawat darurat demi menyelamatkan nyawa atau mencegah keparahan dan/atau kecacatan pada pasien. Lulusan dokter mampu menentukan rujukan yang paling tepat bagi penanganan pasien selanjutnya. Lulusan dokter juga mampu menindaklanjuti sesudah kembali dari rujukan.

# SKDI 2012

**Tingkat Kemampuan 4: mendiagnosis, melakukan penatalaksanaan secara mandiri dan tuntas**

Lulusan dokter mampu membuat diagnosis klinik dan melakukan penatalaksanaan penyakit tersebut secara mandiri dan tuntas.

**4A.** Kompetensi yang dicapai pada saat lulus dokter

**4B.** Profisiensi (kemahiran) yang dicapai setelah selesai internsip dan/atau Pendidikan Kedokteran Berkelanjutan (PKB)

# Lungs

## **Normal anatomy & histology!!**


- Paired intrathoracic organs → lobes
- Right → 3 lobes
- Left → 2 lobes






**Figure 5-1 Normal lungs, gross**

The external surfaces in radiologic orientation show upper, middle, and lower lobes on the right and upper and lower lobes on the left (right lung at left of *left panel*). In the *right panel* the cross-section of normal right lung shows minimal posterior and inferior congestion. There is minimal anthracotic pigment from dust in the air breathed in, scavenged by pulmonary macrophages, and transferred to pleural lymphatics to make them appear grayish black.




**Figure 5-2 Normal lungs, radiographs**

These chest radiographs reveal the normal posterior-anterior (PA) (*left*) and lateral (*right*) projection appearance of the lungs in a normal man. The darker air density represents the aerated lung parenchyma, with soft tissue and bone of the chest wall and hilum brighter. The normal PA heart shadow is about the width of the left lung.




#### Figure 5-4 Normal lung, CT image

This chest CT scan at soft-tissue density reveals the normal appearance of the right (\*) and left (X) lungs—essentially black from air density—in a normal man. Contrast material in the bloodstream gives the right (■) and left (□) chambers of the heart and the aorta (+) a bright appearance. Bone of the vertebral body and ribs also appears bright. The AP diameter is normal.



**Figure 5-5 Normal adult lung, microscopic**

The delicate alveolar walls of the lung are seen here at high magnification. The attenuated cytoplasm of the alveolar type I epithelial cells cannot easily be distinguished from the endothelial cells of the capillaries that are present within the alveolar walls. These thin alveolar walls provide for efficient gas exchange so that the alveolar-arterial (A-a) oxygen gradient is typically less than 15 mm Hg in young, healthy individuals, although the A-a gradient may increase to greater than 20 mm Hg in elderly individuals. Occasional alveolar macrophages (\*) can be found within the alveoli. The type II pneumocytes (▲) produce surfactant that reduces surface tension to increase lung compliance and help keep the alveoli expanded.




- Endothel
- Interstitium
- Alveolar epithelium:
  - Type I (respiration)
  - Type II (surfactant, stem cell)
- Macrophage alveolar (dust cell)

# Primary Lung Disease

- **Airways**
- Interstitium
- Vascular

# Atelectasis (Collapse)



- Loss of lung volume → inadequate expansion
- Mechanism:
  - Resorption: obstruction → mucopurulent plug. Bronchial asthma, aspiration, chronic bronchitis
  - Compression: accumulation fluid, blood, air → pleural cavity.
  - Contraction/ cicatrization: local/ generalized fibrotic

# Acute Lung Injury (ALI) – Acute Respiratory Distress Syndrome (ARDS)





- Abrupt onset, significant hypoxemia
- Bilateral pulmonary infiltrate
- Epithelial/ pneumocytes – endothelial injury
- Severe ALI → ARDS (acute respiratory distress syndrome)
- Histopathology: Diffuse alveolar damage (DAD)

**Table 12-1** Clinical Disorders Associated with the Development of Acute Lung Injury/Acute Respiratory Distress Syndrome

Direct Lung Injury	Indirect Lung Injury
<b>Common Causes</b>	
Pneumonia	Sepsis
Aspiration of gastric contents	Severe trauma with shock
<b>Uncommon Causes</b>	
Pulmonary contusion	Cardiopulmonary bypass
Fat embolism	Acute pancreatitis
Near-drowning	Drug overdose
Inhalational injury	Transfusion of blood products
Reperfusion injury after lung transplantation	Uremia



Modified from Ware LB, Matthay MA: The acute respiratory distress syndrome. *N Engl J Med* 342:1334, 2000.





**Figure 15-4** Diffuse alveolar damage (acute respiratory distress syndrome). Some of the alveoli are collapsed, while others are distended. Many are lined by hyaline membranes (*arrows*).

**Figure 15-3** The normal alveolus (*left side*) compared with the injured alveolus in the early phase of acute lung injury and acute respiratory distress syndrome. (Modified with permission from Matthay MA, Ware LB, Zimmerman GA: The acute respiratory distress syndrome. *J Clin Invest* 122:2731, 2012.) *IL-1*, interleukin-1; *MIF*, migration inhibitory factor; *PAF*, platelet activating factor; *TNF*, tumor necrosis factor.



- Left: ALI & ARDS – pink hyaline membrane
- Right: healing stage – type II pneumocyte

**Obstructive??**

**VS**

**Restrictive??**


# Obstructive lung disease

- **Emphysema** → **COPD**
- **Chronic bronchitis** → **COPD**
- **Asthma**
- **Bronchiectasis**

**Table 15-3 Disorders Associated with Airflow Obstruction: The Spectrum of Chronic Obstructive Pulmonary Disease**

Clinical Term	Anatomic Site	Major Pathologic Changes	Etiology	Signs/Symptoms
Chronic bronchitis	Bronchus	Mucous gland hyperplasia, hypersecretion	<u>Tobacco smoke, air pollutants</u>	Cough, sputum production
Bronchiectasis	Bronchus	Airway dilation and scarring	Persistent or severe infections	Cough, purulent sputum, fever
Asthma	Bronchus	Smooth muscle hyperplasia, excess mucus, inflammation	Immunologic or undefined causes	Episodic wheezing, cough, dyspnea
Emphysema	Acinus	Airspace enlargement; wall destruction	<u>Tobacco smoke</u>	Dyspnea
Small-airway disease, bronchiolitis*	Bronchiole	Inflammatory scarring/obliteration	Tobacco smoke, air pollutants, miscellaneous	Cough, dyspnea


\*Can be seen with any form of obstructive lung disease or as an isolated finding.




**Figure 12–5** Schematic representation of overlap between chronic obstructive lung diseases.

# Emphysema

- Irreversible/ permanent enlargement
- Walls destruction, fibrosis (-)
- Distal terminal bronchiole
- Subtypes:
  - **Centriacinar** (smoking related)
  - **Panacinar** ( $\alpha$ 1-antitrypsin def)
  - Distal acinar
  - Irregular





**Figure 12-7** Loss of cellular homeostasis in emphysema pathogenesis. Exposure to inhaled toxins (such as cigarette smoke) leads to epithelial cell death, inflammation, and extracellular matrix proteolysis. In susceptible persons, mesenchymal cell survival and reparative functions are impaired by direct effects of inhaled toxic substances and inflammatory mediators and by the loss of the peri- and extracellular matrix. The result is loss of structural cells of the alveolar wall and the associated matrix components.

# Emphysema



HE 40X





# Chronic bronchitis

- **Persistent & Productive** cough **3 months, 2 consecutive years**
- Cigarette smoking, air pollutant



**Figure 12-10** Chronic bronchitis. The lumen of the bronchus is above. Note the marked thickening of the mucous gland layer (approximately twice-normal) and squamous metaplasia of lung epithelium.  
(From the Teaching Collection of the Department of Pathology, University of Texas, Southwestern Medical School, Dallas, Texas.)


# Asthma

## Hallmarks:


- Intermittent and reversible airway obstruction
- Chronic inflammation with eosinophils
- Smooth muscle hypertrophy and hyperreactivity
- Increased mucus secretion
- Significant incidence increase in western world → “Hygiene Hypothesis”

# Asthma


**A. NORMAL AIRWAY**




**B. AIRWAY IN ASTHMA**



**C. TRIGGERING OF AST**




**D. IMMEDIATE PHASE (MINUTES)**



**E. LATE PHASE (HOURS)**

# Bronchiectasis


- Obstruction and chronic persistent infection
- Destruction: muscle – elastic tissue
- Permanent dilation: bronchi – bronchioles
- Secondary: post pneumonia, **TB**



# Pulmonary Infection


## **PNEUMONIA**

- 1/6 all deaths in US, Indonesia?
- Local defense compromised:
  - Loss/ suppression cough reflex (coma, anesthesia, drug) → aspirated gastric content
  - Injury mucociliary (cigarette smoke, viral disease)
  - Accumulation of secretion (bronchial obstruction)
  - Interference phagocytic/ bactericidal action of alveolar macrophages (alcohol, tobacco smoke)
  - Pulmonary congestion and edema
- Streptococcus pneumonia > 90%
- Bronchopneumonia – lobar pneumonia
- Anatomic n radiologic




Bronchopneumonia

Lobar pneumonia



**BLURRY.....**

**Classify – etiology or clinical settings**



A. INNATE IMMUNE DEFENSES

B. ADAPTIVE IMMUNE DEFENSES



# CAP - HAP


- Community acquired pneumonia  
S. pneumonia, H. influenzae,....
- Hospital acquired pneumonia  
P. aeruginosa, K. pneumonia,....
- Community acquired atypical pneumonia
- Aspiration pneumonia

# CAP - HAP

Era before antibiotics

Morphology: congestion – red hepatization –  
gray hepatization – resolution

# Pneumonia



# Chronic pneumonia

- Tuberculosis (TB)
- Histoplasmosis
- Blastomycosis
- Coccidioidomycosis

# Tuberculosis

- M. Tbc
- Chronic granulomatous disease
- Lung – extrapulmonal

INCREASING IMMUNITY

Localized lesions,  
more caseation

Spreading lesions,  
little caseation

Primary infection

Scar

Scar

HEALED LESIONS

(organisms not viable)

LATENT LESIONS

(organisms dormant;  
pulmonary or extrapulmonary)

LOCALIZED CASEATING  
DESTRUCTIVE LESIONS

(pulmonary or extrapulmonary)

Caseation

Caseation  
in lymph node

Reactivation

SECONDARY  
TUBERCULOSIS

Cavity

Caseation

Scar

Caseation

Reinfection

PRIMARY COMPLEX

(localized caseation)

PROGRESSIVE PRIMARY TB

Massive hematogenous dissemination

Liver

MILIARY TB

Spleen

PROGRESSIVE SECONDARY TB

Massive hematogenous  
dissemination

MILIARY TB



Weeks

TIME

Years

# Lung Tumors


Both sexes




Lung cancer: 1<sup>st</sup> most frequently diagnosed and 1<sup>st</sup> leading cause of death

# Lung Tumors


B




Males



C



Females





# WHO, 2004

**Table 1.06**

Stage of lung carcinoma at presentation by histologic subtype. SEER data 1983-1987.  
Modified, from reference {192}.

Stage	Squamous	Adenocarcinoma	Small cell	Large cell
Localized	21.5%	22.2%	8.2%	15.2%
Regional	38.5%	33.1%	26.1%	31.5%
Distant	25.2%	35.9%	52.8%	40.3%
Unstaged	14.8%	8.8%	12.8%	12.9%

**60 – 70%**

Poor prognosis...

# Lung tumors

- Benign - malignant, epithelial – mesenchymal
- 90-95 % → carcinoma
- 5-10%: carcinoids, lymphoma
- **SMOKING RELATED...TOBACCO EPIDEMIC !!!**  
**polycyclic aromatic hydrocarbons, such as benzopyrene, anthracenes, radioactive isotopes**
- EGFR – KRAS mutation → personalized therapy

# Lung tumors

## TOBACCO EPIDEMIC !!!

Lung cancer is one of the most preventable cancers. Most lung cancers could be avoided by eliminating smoking initiation and increasing smoking cessation among current smokers. This requires a comprehensive tobacco control program that includes raising the price of tobacco products through excise taxes, banning smoking in public places and tobacco sales to minors, restricting tobacco advertising and promotion, counteradvertising, and providing treatment and counseling for tobacco dependence. In the United States, comprehensive tobacco control programs in many states, including California and New York, have markedly decreased smoking rates and accelerated the reduction in

# Prior WHO 2004 classification

- Tumors other than small cell carcinoma (SCLC) lumped together → non-small cell carcinoma (NSCLC)
- No therapeutic implication for subtyping
- Light microscopy → only H&E stained

# WHO Lung, Thymus and Heart (2015)

Non small cell lung cancer:

- **Adenocarcinoma**
- **Squamous cell carcinoma**
- Large cell neuroendocrine (NE) carcinoma
- Neuroendocrine/ Carcinoid tumor: Typical and Atypical
- Adenosquamous carcinoma
- Pleomorphic carcinoma
- Spindle cell carcinoma
- .....


# WHO Lung, Thymus and Heart (2015)

- Molecular biology and patient treatment
- EGFR gene mutation in lung adenocarcinoma  
→ targeted therapy (gefitinib, erlotinib) →  
Significant response
- ALK inhibitor → crizotinib → adenocarcinoma  
with ALK fusion
- Molecular testing for treatment selection in  
lung cancer

# Major Genetic Changes in Lung Cancer

## “Oncogene Addiction”


Alterations	Small cell carcinoma (%)	Adenocarcinoma (%)	Squamous cell carcinoma (%)
<b>Mutation</b>			
<i>BRAF</i>	0	< 5	0
<i>EGFR</i> Caucasian	< 1	10–20	< 1
<i>EGFR</i> Asian	< 5	35–45	< 5
<i>ERBB2/HER2</i>	0	< 5	0
<i>KRAS</i> Caucasian	< 1	15–35	< 5
<i>KRAS</i> Asian	< 1	5–10	< 5
<i>PIK3CA</i>	< 5	< 5	5–15
<i>RB</i>	> 90	5–15	5–15
<i>TP53</i>	> 90	30–40	50–80
<b>Amplification</b>			
<i>EGFR</i>	< 1	5–10	10
<i>ERBB2/HER2</i>	< 1	< 5	< 1
<i>MET</i>	< 1	< 5	< 5
<i>MYC</i>	20–30	5–10	5–10
<i>FGFR1</i>	< 1	< 5	15–25
<b>Gene rearrangement</b>			
<i>ALK</i>	0	5	< 1
<i>RET</i>	0	1–2	0
<i>ROS1</i>	0	1–2	0
<i>NTRK1</i>	0	< 1	0
<i>NRG1</i>	0	< 1	0



# Adenocarcinoma

- Def: malignant epithelial tumor with glandular differentiation, mucin production or pneumocyte marker expression.
- Incidence → Lung cancer trends by histologic type
- Changes in design and characteristic of manufactured cigarettes
- Clinical features: variety of symptoms/ no symptoms at all. Progressive shortness of breath, cough, chest pain/ pressure, hoarseness, loss of voice, hemoptysis.
- Localization: **lung periphery**
- Adeno markers: TTF1, Napsin A





**Figure 1.**

Trends in lung cancer incidence rates (age-adjusted 2000 US standard) from 1977 to 1981 through 2006 to 2010 in the SEER 9 registries by histologic type.




# Adenocarcinoma

## US Surgeon General's 2014 report:

1. The evidence is sufficient that the **risk of developing adenocarcinoma** of the lung from cigarette smoking has **increased since 1960s**
2. The evidence is sufficient that the **risk of adenocarcinoma in smokers** results from **changes in the design and composition of cigarettes since the 1950s**
3. The evidence is not sufficient to specify which design changes are responsible, **suggestive ventilated filters and increased levels of tobacco specific nitrosamines**
4. The evidence shows that the **decline of squamous cell carcinoma follows the trend of declining smoking prevalence**


• US public health service office of the surgeon general and national center for chronic disease prevention and health promotion. The health consequences of smoking – 50 years of progress. 2014

# Adenocarcinoma Cytology



- Travis WD. Diagnosis of lung cancer in small biopsies and cytology. Implications of the 2011 international association for study of lung cancer/ American thoracic society/ European respiratory society classification. Arch pathol lab med. 2013

# Adenocarcinoma Histopathology




- Travis WD. Diagnosis of lung cancer in small biopsies and cytology. Implications of the 2011 international association for study of lung cancer/ American thoracic society/ European respiratory society classification. Arch pathol lab med. 2013

# Squamous cell carcinoma

- Def: malignant epithelial tumor shows keratinization and/or intercellular bridges
- Clinical features: similar to adenocarcinoma
- Localization: arise in main or lobar bronchus
- Squamous marker: p40, p63, CK5/6


# Squamous cell carcinoma



- Travis WD. Diagnosis of lung cancer in small biopsies and cytology. Implications of the 2011 international association for study of lung cancer/ American thoracic society/ European respiratory society classification. Arch pathol lab med. 2013

# Small Cell Lung Cancer (SCLC)

- Small cells, scant cytoplasm, ill defined cell border, finely granular chromatin, inconspicuous nucleoli
- Expression neuroendocrine marker
- Hilar/ perihilar mass, lymphadenopathy (+)



Terima kasih...